The exemption may be short-lived if President Trump makes good on threats to use tariffs as leverage to bring drug production ...

US-based pharmaceutical company Moleculin Biotech has begun dosing subjects in its Phase III MIRACLE trial of Annamycin with ...

Moving Biotech secures €7.6 million under France 2030 grant for pioneering disease-modifying osteoarthritis drug: Lille, France Wednesday, April 9, 2025, 09:00 Hrs [IST] 4Movin ...

Drugmakers are lobbying Trump to phase in tariffs on imported pharmaceutical products in hopes of reducing the sting from the ...

Two areas that suffered relatively light damage, however, were pharmaceuticals and biotech. The main reason ... they were concentrating on levies being phased in, as opposed to the full 25% ...

We recently published a list of 10 Hot Biotech Stocks Under $5. In this article, we are going to take a look at where Amylyx ...

Biotech company Zealand Pharma A/S, an innovator in peptide-based medicines, announced the positive topline results from its phase 3 trial of glepaglutide on Friday. A total of 106 patients with ...

This investment comes as LGM Pharma experiences sustained growth in prescription drug projects ... Strengthening U.S. Pharmaceutical Manufacturing As supply chain disruptions, tariffs, and ...

4Moving Biotech (4MB), a spin-off of 4P-Pharma dedicated to developing first-in-class treatment that modify the natural history of knee osteoarthritis, announced that it has been authorized by Health ...

Zealand Pharma announces completion of enrollment in the Phase 2b ZUPREME-1 trial of ... (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide ...